Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$52.86
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
iRadimed Analyst Ratings and Price Targets | NASDAQ:IRMD | Benzinga
iRadimed Corp has a consensus price target of $72 based on the ratings of 1 analysts. The high is $72 issued by Roth MKM on February 14, 2025. The low is $72 issued by Roth MKM on February 14, 2025. The 3 most-recent analyst ratings were released by Roth MKM on February 14, 2025, August 2, 2024, and April 22, 2024, respectively. With an average price target of $65.67 between Roth MKM, there's an implied 24.23% upside for iRadimed Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Roth MKM
1calculated from analyst ratings
Analyst Ratings for iRadimed
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/14/2025 | Buy Now | 36.21% | Roth MKM | Jason Wittes53% | $60 → $72 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2024 | Buy Now | 13.51% | Roth MKM | Jason Wittes53% | $65 → $60 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | 22.97% | Roth MKM | Jason Wittes53% | → $65 | Reinstates | → Buy | Get Alert |
FAQ
What is the target price for iRadimed (IRMD) stock?
The latest price target for iRadimed (NASDAQ:IRMD) was reported by Roth MKM on February 14, 2025. The analyst firm set a price target for $72.00 expecting IRMD to rise to within 12 months (a possible 36.21% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for iRadimed (IRMD)?
The latest analyst rating for iRadimed (NASDAQ:IRMD) was provided by Roth MKM, and iRadimed reiterated their buy rating.
When was the last upgrade for iRadimed (IRMD)?
There is no last upgrade for iRadimed
When was the last downgrade for iRadimed (IRMD)?
There is no last downgrade for iRadimed.
When is the next analyst rating going to be posted or updated for iRadimed (IRMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of iRadimed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for iRadimed was filed on February 14, 2025 so you should expect the next rating to be made available sometime around February 14, 2026.
Is the Analyst Rating iRadimed (IRMD) correct?
While ratings are subjective and will change, the latest iRadimed (IRMD) rating was a reiterated with a price target of $60.00 to $72.00. The current price iRadimed (IRMD) is trading at is $52.86, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.